Background Botulinum Toxin type-A (BoNT-A) is a safe and effective treatment for reducing
spasticity in children with cerebral palsy (CP). BoNT-A injection into the muscles alleviate …

There has been a considerable increase over the last few years in the use of botulinum toxin
type A in the treatment of adults with spasticity. It is considered the pharmacological …

Objective To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb
spasticity previously treated with botulinum toxin A (BoNT‐A). Design A post hoc analysis …

A systematic review with the Sachett model of evidence-based medicine of the use of
Botulinum toxin type A (BTX) for intervention in children with Cerebral Palsy (CP) is …

Botulinum neurotoxin (BoNT) can be injected to achieve therapeutic benefit across a large
range of clinical conditions. To assess the efficacy and safety of BoNT injections for the …

Objective: To assess the efficacy of botulinum toxin A injection for the management of
spastic calf muscles in children with cerebral palsy. Data sources: We reviewed all relevant …

Background: This study aims to assess current practices of Canadian physicians providing
botulinum toxin-A (BoNT-A) treatments for children with hypertonia and to contrast these with …

An interdisciplinary group of experienced botulinum toxin users and experts in the field of
movement disorders was assembled, to develop a consensus on best practice for the …

This retrospective cohort study reviewed set goals and their outcomes of children and
adolescents with severe cerebral palsy who received botulinum toxin A in 2008 and 2009 …

Botulinum toxin type A (BoNT-A) represents the gold standard therapy for focal spasticity
and related disorders also in acquired brain injury including stroke. Since 1989, the …